22 results about "Interferon regulatory factors" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses application of a swine STING molecular agonist SR-717 in preparation of a pseudorabies virus infection resisting medicine. The swine STING molecular agonist SR-717 can be stably combined with swine STING protein, the promoter activity of a downstream signal molecule interferon regulatory factor 3 (IRF3) and I-type interferon (IFN beta) is enhanced, PRV replication can be remarkably inhibited, the virus load is reduced, and pathological changes of infected mouse lung, brain and other tissues are reduced. The SR-717 provided by the invention has good targeting property and immune activation ability, and is suitable for intervention treatment of porcine pseudorabies virus infection.

The invention relates to the inhibition of expression of interferon regulatory factor-4 (IRF4) using RNA interference, chemically-modified oligonucleotides, and / or chimeric siRNA multivalent combinations. The invention further relates to methods of treating IRF4 related conditions such as multiple myeloma.

Compounds that include a cyclic cell penetrating peptide and a therapeutic moiety modulates Interferon Regulatory Factor-5 (IRF-5) activity in an immune cell. The therapeutic moiety is a therapeutic protein, a small molecule, or an antisense compound. Methods include administering the compound to cells or subjects to modulate IRF-5 activity. Methods include treating diseases associated with IRF-5 using the compounds.

Compounds are provided that are useful for inhibiting interferon regulatory factor 4 (IRF4). Also provided are pharmaceutical compositions comprising such compounds and methods for treating diseases related to IRF4 activity, such as cancer, using such compounds.

The invention relates to medical application of IRF9 in prevention and treatment of trastuzumab (TRZ) cardiotoxicity, and belongs to the technical field of biological medicine. The invention reveals that the expression of the interferon regulatory factor 9 (IRF9) in the TRZ cardiotoxic myocardial tissue is up-regulated for the first time, and myocardial damage is aggravated by promoting pyroptosis of myocardial cells. On the basis, the invention provides the IRF9 as a diagnostic marker of TRZ cardiotoxicity, and provides an application of an IRF9 low expression vector or small interfering RNA (siRNA) in preparation of drugs for preventing or treating TRZ cardiotoxicity. Animal experiments show that cardiac function decline, cardiac hypertrophy and fibrosis caused by TRZ can be remarkably improved by myocardial cell specific low-expression IRF9. The invention provides a new target spot and an intervention strategy for clinical prevention and treatment of TRZ cardiotoxicity.

The present disclosure provides oncolytic viruses expressing a modulator of interferon regulatory factors (IRFs), and compositions comprising thereof. The present disclosure further provides methods of using said oncolytic viruses and compositions for treating cancer, and for improving a subject's responsiveness to an immunomodulatory agent (e.g., an immune checkpoint inhibitor).

The invention discloses application of piperlongumine in treating and preventing lung injury, and belongs to the technical field of medicines. Aiming at the technical bottlenecks of limited treatment means and high case fatality rate of the existing acute lung injury (ALI) / acute respiratory distress syndrome (ARDS), the invention discovers that piperlongumine can specifically inhibit cGAS-STING signal channel activation for the first time, and expression release of inflammatory factors IFN-beta, IL-6 and TNF-alpha is reduced by regulating phosphorylation of a downstream interferon regulatory factor 3 (IRF3). In-vitro experiments prove that piperlongumine inhibits ISD-induced inflammatory response in a dose-dependent manner, and in-vivo experiments show that piperlongumine can significantly relieve LPS-induced mouse acute lung tissue inflammatory cell infiltration, reduce serum IL-6 and TNF-alpha levels, and improve lung tissue pathological injury. According to the invention, the medicinal application of piperlongumine is expanded, a new lung injury treatment scheme based on natural active compounds is provided, and the piperlongumine can be widely applied to prevention and treatment of acute lung injury and related inflammatory lung diseases.

The present disclosure provides compositions and methods for inhibiting hepatitis B virus (HBV) in infected cells. Exemplary methods include contacting an infected cell with one or more agents that induce interferon regulatory factor 3 (IRF3) activation in the infected cell. In some embodiments, the one or more agents include a nucleic acid molecule containing a pathogen-associated molecular pattern (PAMP), a small molecule agent (e.g., a benzothiazole derivative molecule), or a combination thereof. In some embodiments, the methods further include contacting the infected cell with an NRTI. The methods can be in vivo methods of treating a subject having an HBV infection, which include administering a therapeutically relevant amount of one or more agents formulated in one or more therapeutically effective compositions. Exemplary compositions are formulated for treating a hepatitis B virus (HBV) infection in a subject, which include: a RIG-I agonist, a vehicle for intracellular delivery, and a pharmaceutically acceptable carrier.

The invention relates to the technical field of medicines, and particularly discloses a pharmaceutical composition based on an IRF7-PTEN signal axis and application of the pharmaceutical composition in spinal cord injury. According to the application, a plurality of spinal cord injury single cell sequencing data sets are integrated, and the interferon regulatory factor 7, namely IRF7, is screened and verified to be a key hub gene for regulating and controlling apoptosis of astrocytes. Knock-down IRF7 significantly inhibits astrocyte apoptosis induced by etoposide, and rotation IRF7 can reverse the effect. In mechanism, the IRF7 promotes cell apoptosis by negatively regulating a PTEN pathway, and the PTEN inhibitor SF1670 can block the IRF7 overexpression mediated apoptosis promoting effect. On the basis, the invention provides a pharmaceutical composition taking the signal axis as a target spot, and the active ingredient of the pharmaceutical composition can be an IRF7 inhibitor or a PTEN inhibitor; the invention also discloses application of the inhibitor in preparation of drugs for treating spinal cord injury. The application provides a new target spot and an effective intervention strategy for treatment of spinal cord injury.

The invention discloses an interferon regulatory factor 4 (IRF4) inhibitor as shown in a formula (1) and a preparation method thereof, and a target product is prepared by taking dinorhydrin as a raw material through reactions such as TBS protection, 4, 4-dimethylation, TBS protection removal, oxidation, esterification, reduction, iodination, cyano substitution, Wittig, hydrolysis, esterification, amidation, condensation and the like. The invention further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM), and further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM). The compound can selectively inhibit the multiplication capacity of IRF4 high-expression myeloma cells, and has a good application prospect in treatment of IRF4 high-expression tumors such as multiple myeloma and lymphoma.

The invention discloses a large yellow croaker interferon i gene promoter sequence and application thereof. By analyzing genome data of the pseudosciaena crocea, the pseudosciaena crocea IFNi gene promoter is cloned, and the sequence of the pseudosciaena crocea IFNi gene promoter is provided, and the sequence is as shown in SEQ ID NO.1. Experiments prove that the sequence has promoter activity, and the activity of the sequence is significantly up-regulated under the induction of a viral nucleic acid simulant Poly (I: C). In addition, the interferon regulatory factor 1 (IRF1) can also be used for remarkably inducing the activity of the IFNi gene promoter of the large yellow croaker. Cloning and activity identification of the promoter provide a good experimental system for researching expression regulation and control of the IFNi gene of the large yellow croaker, create conditions for constructing an efficient expression vector to express an exogenous gene or applying the expression vector to transgenic fish construction by using the promoter, and have important theoretical and practical significance.

The present application relates to a kind of biomarker associated with pulmonary fibrosis and its application.The biomarker includes interferon regulatory factor 8.The present application utilizes the classic bleomycin induced pulmonary fibrosis model, induces pulmonary fibrosis in experimental animal mouse, carries out transcriptome level analysis, finds that the expression level of bone marrow endothelial rich interferon regulatory factor 8 in pulmonary fibrosis mouse model is reduced, further test finds that the expression level of interferon regulatory factor 8 (such as by agonist regulation etc.) in mouse model can delay the occurrence and development of pulmonary fibrosis, indicates that IRF8 can be used as the new target of pulmonary fibrosis diagnosis, treatment, provides new target, new strategy for the treatment of pulmonary fibrosis.

The invention relates to compounds useful for degradation of interferon regulatory factor 4 (IRF4), pharmaceutical compositions comprising such compounds and methods for treating diseases related to IRF4 activity, such as cancer, using such compounds.

Provided are conjugates comprising a targeting moiety or antigen conjugated to a CpG oligonucleotide. In some instances, the targeting moiety or antigen conjugated to the 3' end region of a CpG oligonucleotide. According to some embodiments, the CpG oligonucleotide comprises a palindromic sequence and / or is one which, in its unconjugated state, activates NF-κB and interferon regulatory factor (IRF) pathways. Compositions comprising the conjugates, as well as methods of using the conjugates, are also provided.

The embodiment of the invention discloses application of cGAMP in prevention of cerebral malaria, and belongs to the technical field of prevention and treatment of zoonosis parasitic diseases. CGAMP is used as a second messenger in the cell, responds to cytoplasm double-stranded DNA synthesis, activates an innate immune STING pathway, the cGAMP is combined with STING, and the STING is collected and phosphorylated, so that further collection and activation of TANK binding kinase 1 (TBK1) are promoted, combination and phosphorylation of interferon regulatory factor 3 (IRF3) are caused, the activated IRF3 stimulates expression of I-type interferon (IFN), and the IFN plays a key role in antivirus and innate immune response, and can be used for preventing and treating the virus and the innate immune response. The IFN-I (IFN-alpha and IFN-beta) plays an important role in plasmodium infection, so that the IFN-I (IFN-alpha and IFN-beta) plays a key recognition role in the plasmodium infection process, cerebral malaria can be prevented, and the life quality of a patient is greatly improved.

This invention relates to a fish interferon regulator IRF4 gene, protein, expression vector, and their applications, belonging to the field of fish molecular immunology technology. The fish interferon regulator IRF4 is derived from the oval pomfret, and the cDNA nucleotide sequence of the oval pomfret IRF4 gene is shown in SEQ ID NO.1. The amino acid sequence of the protein encoded by the oval pomfret IRF4 gene is shown in SEQ ID NO.2. This invention also provides an expression vector containing the oval pomfret IRF4 gene, and an anti-Vibrio harveyi infection preparation containing the protein or a eukaryotic expression vector. The oval pomfret IRF4 protein of this invention can promote the respiratory burst activity and phagocytic capacity of oval pomfret head kidney macrophages. Overexpression in oval pomfret... Believe After IRF4 is activated, the body's antibacterial ability can be significantly improved, and it can be used as an immune enhancer.

The invention relates to a biological marker related to pulmonary fibrosis and application of the biological marker. The biomarker comprises an interferon regulatory factor 8. A classical bleomycin-induced pulmonary fibrosis model is utilized to induce pulmonary fibrosis in an experimental animal mouse, transcriptome level analysis is carried out, and it is found that the expression level of the interferon regulatory factor 8 enriched with bone marrow endothelium in the pulmonary fibrosis mouse model is reduced. Further tests find that the occurrence and development of the pulmonary fibrosis can be delayed by improving the expression level of the interferon regulatory factor 8 in a mouse model (such as regulation and control by an agonist and the like), which indicates that the IRF8 can be used as a new target for diagnosis and treatment of the pulmonary fibrosis, and a new target and a new strategy are provided for treatment of the pulmonary fibrosis.

It is an object of the present invention to provide a pyrrole imidazole polyamide (PIPA), which suppresses the expression of cytokines essential for activation of immune response, in particular, the expression of type I IFN, at a transcription stage. More specifically, the present invention relates to a PIPA that specifically binds to the binding region of an IRF (IFN regulatory factor) family transcription factor. Specifically, the present PIPA is a PIPA that binds to 5′-GAAAGTG-3 (SEQ ID No: 1) or a modified sequence thereof, 5′-GAAAG-3′ (SEQ ID No: 9) or a modified sequence thereof, 5′-GAAAA-3′ (SEQ ID No: 15) or a modified sequence thereof, or 5′-GAAAC-3′ (SEQ ID No: 21) or a modified sequence thereof.

The invention relates to a bone marrow-like endothelial cell as well as a preparation method and application thereof. The bone marrow-like endothelial cell comprises a human umbilical vein endothelial cell over-expressing an interferon regulatory factor 8 gene. Based on single cell transcriptome data of multi-organ endothelial cells, an interferon regulatory factor 8 is screened as a transcription factor for regulating bone marrow endothelial cell characteristics. By overexpressing the interferon regulatory factor 8, not only can the up-regulation of a bone marrow endothelial specific gene be promoted, but also the human primary endothelial cell line can be closer to bone marrow endothelial cells in transcriptional level and function, so that the bone marrow endothelial cells are effectively simulated in vitro.

The present disclosure relates to use of a compound in preparation of a medicament for prophylaxis and treatment of inflammatory tissue damage. The present disclosure provides use of a compound in preparation of a medicament for prophylaxis and treatment of tissue damage, and the compound has a structure represented by formula I. The compound having the structure represented by formula I provided by the present disclosure can inhibit transcriptional activity of interferon regulatory factor 1 (IRF1), have prophylactic and therapeutic effects on tissue damage, enhance cell proliferation ability after tissue cell injury, and repair injured tissues. The compound having the structure represented by formula I provided by the present disclosure has important significance and application value in the preparation of the medicament for prophylaxis and treatment of tissue damage, particularly in the preparation of a medicament for inflammatory injuries of skin tissues induced by radiation and / or oxidation.

The invention provides application of venenum bufonis active molecules in preparation of cGAS-STING pathway inhibitors, and particularly belongs to the technical field of protein inhibitors. Starting from a downstream interferon regulatory factor of a cGAS-STING pathway, the venenum bufonis active molecule is found to have relatively strong inhibitory activity on the cGAS-STING pathway through screening. The ulcerative colitis resisting activity evaluation on the active molecule arenobufagin of the venenum bufonis finds that the arenobufagin has a good relieving effect on the ulcerative colitis, the colon length can be obviously improved, and release of serum inflammatory factors of mice with the ulcerative colitis can also be inhibited. Finally, the venenum bufonis active molecule can be used as a cGAS-STING pathway inhibitor, plays a role in resisting ulcerative colitis, and lays a foundation for clinically developing medicines for treating ulcerative colitis.

The invention relates to a gene of a humpback perch interferon regulatory factor IRF1 and application of the gene as an immunologic adjuvant, and belongs to the field of molecular biology technology and application, the sequence of the humpback perch IRF1 gene is as shown in SEQ ID NO.1, and the amino acid sequence of protein coded by the gene is as shown in SEQ ID NO.2. The eukaryotic expression plasmid of the humpback perch IRF1 constructed by the invention can be used as an immunologic adjuvant of the DNA vaccine pCTssj to improve the immune effect of the humpback perch IRF1 against vibrio harveyi infection, can be developed into an immune preparation, and has good practical application value.